Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review

Abstract

Syndrome of inappropriate antidiuresis (SIAD) is a common paraneoplastic syndrome commonly associated with thoracic malignancies, gastrointestinal cancers and kidney tumors. It is defined as hyponatremia in euvolemic patients, often due to abnormal secretion of antidiuretic hormone by tumor cells. Tolvaptan, a vasopressin-2-receptor antagonist, is currently recommended for patients affected by SIAD with mild or moderate symptoms. Among patients with prostatic cancer, SIAD represents a rare condition but it is frequently associated with poorly differentiated adenocarcinoma or pure small-cell carcinoma histotype. We report a case of SIAD appeared at disease progression in a 60-year-old male patient with acinar adenocarcinoma with neuroendocrine differentiation together with a literature review.

Keywords

Hyponatremia / prostate cancer / syndrome of inappropriate antidiuresis / neuroendocrine differentiation

References

[1] Torre LA,Siegel RL,Lortet-Tieulent J.Global cancer statistics, 2012..CA Cancer J Clin2015;65:87-108

[2] Humphrey PA,Cubilla AL,Reuter VE.The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours..Eur Urol2016;70:106-19

[3] Hugosson J,Aus G,Khatami A.Mortality results from the Göteborg randomised population-based prostate-cancer screening trial..Lancet Oncol2010;11:725-32 PMCID:PMC4089887

[4] Hong MK,Namdarian B,Grummet J.Paraneoplastic syndromes in prostate cancer..Nat Rev Urol2010;7:681-92

[5] Castillo JJ,Justice E.Diagnosis and management of hyponatremia in cancer patients..Oncologist2012;17:756-65 PMCID:PMC3380874

[6] Grohé C,Runkle I.SIADH: differential diagnosis and clinical management..Endocrine2017;55:311-9

[7] Petereit C,Teber I,Grohé C.A rapid and efficient way tomanage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan..BMC Pulm Med2013;13:55 PMCID:PMC3851291

[8] Palmer BF,Lader M.Causes and management of hyponatremia..Ann Pharmacother2003;37:1694-702

[9] Ghali JK.Mechanisms, risks, and new treatment options for hyponatremia..Cardiology2008;111:147-57

[10] Berghmans T,Body JJ.A prospective study on hyponatraemia in medical cancer patients: epidemiology, etiology and differential diagnosis..Support Care Cancer2000;8:192-7

[11] Waikar SS,Curhan GC.Mortality after hospitalization with mild, moderate, and severe hyponatremia..Am J Med2009;122:857-65 PMCID:PMC3033702

[12] Corona G,Parenti G,Verbalis JG.Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis..PLoS One2013;8:e80451 PMCID:PMC3867320

[13] Boscoe A,Verbalis JG.Cost of illness of hyponatremia in the United States..Cost Eff Resour Alloc2006;4:10 PMCID:PMC1525202

[14] Berardi R,Castagnani M,Marcucci F.Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients..Support Care Cancer2015;23:3095-101

[15] Grohé C,Burst V.Hyponatraemia--SIADH in lung cancer diagnostic and treatment algorithms..Crit Rev Oncol Hematol2015;96:1-8

[16] Hu J,Jin L,Zhao Y.Pure small-cell carcinoma of the prostate presenting with increasing prostate-specific antigen levels: A case report and review of the literature..Mol Clin Oncol2018;9:197-200 PMCID:PMC6083420

[17] Wang W.Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases..Am J Surg Pathol2008;32:65-71

[18] Deorah S,Raman R,Donovan JF.Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study..BJU Int2012;109:824-30

[19] Yuan TC,Lin MF.Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells..Endocr Relat Cancer2007;14:531-47

[20] Miyoshi Y,Kitami K,Kubota Y.Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy..BJU Int2001;88:982-3

[21] Lapuk AV,Wyatt AW,McConeghy BJ.From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer..J Pathol2012;227:286-97 PMCID:PMC3659819

[22] Péqueux C,Hagelstein MT,Legros JJ.Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway..Endocr Relat Cancer2004;11:871-85

[23] North WG,Akerman B.Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody..Front Oncol2014;11:4-16 PMCID:PMC3920095

[24] Miretti VS,Sierra JT,Laborié MV.Prostate carcinoma and syndrome of inappropriate antidiuretic hormone secretion..Medicina (B Aires)2018;78:290-3(in Spanish)

[25] Kawai S,Tsukamoto Y,Suzuki H.Small cell carcinoma of the prostate expressing prostate-specific antigen and showing syndrome of inappropriate secretion of antidiuretic hormone: an autopsy case report..Pathol Int2003;Dec53:892-6